Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population.
Zoé Van de WyngaertBenjamin CarpentierLaurent PascalPauline Lionne-HuygheIsabelle LeducMicha SrourMichele VasseurHelene DemarquetteLouis TerriouCharles HerbauxSalomon ManierJean-Baptiste BossardSarah BarbieuxPaul ChauvetAlexandre WillaumeMorgane NudelClaire BoriesJean-Baptiste GibierThierry FaconEileen Mary BoylePublished in: British journal of haematology (2019)